Heading Toward Profitability, Vertex Files NDA for CF Drug
By Jennifer Boggs
Thursday, October 20, 2011
Even as analysts are looking for Vertex Pharmaceuticals Inc. to report a third-quarter profit next week on better-than-expected sales of hepatitis C drug Incivek (telaprevir), the Cambridge, Mass.-based biotech is gearing up to launch a second drug.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.